Ireland-headquartered fish oil-based heart drug specialist Amarin Corporation (Nasdaq: AMRN) announced that it has appointed Aaron Berg, currently Amarin’s executive vice president and president of the US business, as president and chief executive (CEO).
The appointment of Mr Berg follows the resignation of Patrick Holt as president and CEO of the company, with the news sending Amarin’s shares down 18% to $0.70.
This is the second CEO appointment in little over a year. In April 2023, Karim Mikhail resigned as president and chief executive of Amarin.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze